Trade Summary

3 days ago, Third Rock Ventures V, L.P., serving as 10% owner at Rapport Therapeutics, Inc. (RAPP), sold 133,618 shares at $40.24 per share, for a total transaction value of $5,377,323.00. Following this transaction, Third Rock Ventures V, L.P. now holds 7,268,315 shares of RAPP.

This sale represents a 2.00% decrease in Third Rock Ventures V, L.P.'s stake in the company. This is considered a medium-conviction trade.

The trade was executed on Monday, May 11, 2026 and publicly disclosed via SEC Form 4 filing on Wednesday, May 13, 2026, 2 days after the trade was made.

Rapport Therapeutics, Inc. operates in the HEALTHCARE sector, specifically within the BIOTECHNOLOGY industry. Insider selling activity in this sector can provide valuable signals about industry trends and company-specific developments.